Pascal Soriot spoke exclusively with CNBC from the site of AstraZeneca's new $1 billion R&D facility in Kendall Square in ...

Pascal Soriot told CNBC that ivonescimab could combine with antibody-drug conjugates to treat tumors that existing ...

AstraZeneca PLC (US) (NYSE:AZN) is on the cusp of unlocking a new growth engine in lung cancer treatment. On September 29, ...

Oct 5 (Reuters) - AstraZeneca said on Monday it would spend more than $1 billion in Massachusetts as part of its broader $50 ...

AstraZeneca just locked in a price to own 12% of Summit Therapeutics that the open market refuses to match, and two clinical ...

CNBC’s Annika Kim Constantino and Pascal Soriot, AstraZeneca CEO, join 'The Exchange' to discuss its $50 billion investment in stateside manufacturing and opening an research and development site in ...

The biopharmaceutical company plans to expand its Massachusetts workforce by over 50% as the industry faces broader headwinds ...

Summit shares surged in after-hours trading following the news of AstraZeneca’s investment, as the two companies plan to ramp ...

CNBC’s Annika Kim Constantino and Pascal Soriot, AstraZeneca CEO, join 'The Exchange' to discuss its $50 billion investment ...

AstraZeneca gets a Buy rating as its core business is still growing while a deep late-stage pipeline gives investors multiple ways for earnings. Click for more.